Josh SitemanWhile global ag tech funding cooled, China stayed concentrated. More than half of its ag tech investment in 2025 went to agricultural biotechnology — state-backed, patient capital with a 20-year horizon.
It moved from selling capacity to selling innovation in pharma. The argument is ag biotech is next.
For those watching food sovereignty in Canada, the strategic intent gap is real.